China is the most populous country in the world, with 1.3 billion people. Its spectacular
economic growth during the past 10 to 15 years was accompanied by an explosive
development in cardiovascular medicine. Just 1 of the areas in which this medical evolution
occurred is a relatively recent but substantial interest in hypertrophic cardiomyopathy (HC).
Despite the presence in China of many public health problems that surpass HC (and other
genetic heart diseases) in sheer magnitude, it is notable that this cardiac disease also …